Company: BLCO
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013244
Chunk: 57

Company: Bausch & Lomb Corp
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 57
---
1) | The amounts included in this column reflect salary earned during the respective year. For 2024, Mr. Saunders did not receive a salary increase; his annual salary is reflected in this column. |

| (2) | The amounts included in this column for 2023 for Messrs. Saunders, Bailey and Stewart reflect the sign-on bonuses paid to such executives in 2023 in connection with the commencement of their employment with the Company. |

| (3) | The amounts reflected in this column for 2024 represent the aggregate grant date fair value of the Bausch + Lomb RSUs and PSUs granted to the NEOs in 2024, computed in accordance with FASB ASC Topic 718 (excluding the effect of estimated forfeitures). The grant date fair values reflected in this column may differ from the approved values reflected in the CD&A because of the accounting methodology used to report the PSUs in this column, as required by SEC rules. The grant date fair value of the PSUs granted to the NEOs during 2024 was calculated based on the probable outcome of the performance conditions as of the grant date, consistent with the estimate of aggregate compensation cost to be recognized over the service period determined as of the grant date under FASB ASC Subtopic 718-10, excluding the effect of estimated forfeitures. The grant date value of the PSUs granted to these NEOs in 2024 and reported in the table above, assuming the highest level of performance conditions will be achieved (200% of target levels, 300% for the Outperformance Award), is $26,602,931 for Mr. Saunders, $8,977,802 for Mr. Eldessouky, $7,700,660 for Mr. Bailey, $6,742,766 for Dr. Hashad, and $6,423,443 for Mr. Stewart. The amount reflected in this column and in this footnote do not represent the actual amounts that will be paid to or realized by our NEOs for awards made during the respective fiscal year. Information regarding the assumptions used to value these awards is set forth in “Note 2-Significant Accounting Policies” and “Note 13-Share Based Compensation” to the audited consolidated financial statements included in the Company’s Annual Report. |

| (4) | The amounts reflected in this column for 2024 represent the aggregate grant date fair value of the Bausch + Lomb Stock Options granted to the NEOs in 2024, computed in